Matricelf - Regenerating the future of medicine

We are developing a platform for autologous 3D printing of tissues and organs that significantly reduce the risk of implant rejection.
Using a biopsy from the patient we develop tissues (cells and scaffold) that we can 3D print, inject or simply place where needed.
In 2019, we printed, for the first time in human history, a three-dimensional human heart from human tissue.
The company performed successful pre-clinical studies in a number of
medical conditions such as Acute Myocardial Infarction, Parkinson's Disease, Age related Macular Degeneration and more.

Matricelf’s technology aims to completely regenerate the future of medicine.
The company completed successful pre-clinical studies in a number of
medical conditions such as acute Myocardial Infarction, Parkinson's Disease, Age related Macular Degeneration and more.

Our first indication is Spinal Cord Injury.
Each year, there are tens of thousands of new cases of traumatic Spinal Cord Injuries that usually lead to paralysis.
Considering the fact that SCI patients have no suggested treatments and are expected to spend their life in a wheelchair motivated us to further develop the technology and specifically SCI implant.
In our pre-clinical animal studies, mice treated with our implants regained their walking ability both in acute and chronic spinal cord injury models.

Every 30 minutes a patient dies while he/she are waiting for an organ transplantation.
Millions around the world are suffering from diseases that involves tissue damage (like diabetes, Parkinson's disease and many more).
Those diseases impose a huge economic, social and medical burden.
Many companies are developing tissue engineering technologies but they all use either cells or scaffold that are not from the same patient, leading to an immune response and organ or tissue rejection.

Matricelf is a biotechnology company in the field of tissue engineering.
The company develops a platform for autologous (personal) 3D printing of tissues and organs that significantly reduce the risk of implant rejection.

Using a single biopsy fr om the patient we develop tissues (cells and scaffold) that we can 3D print, inject or simply place wh ere needed.

Many companies in the world are in the area of Tissue engineering but none of them uses a complete autologous tissue like we do.
Our solution provides for the first time a completely personalized treatment where both the material and cells are derived from the patient, therefore, the implant do not provoke an immune response. Additionally, in this approach, the cells are differentiated within their final ECM 3D construct which allows mimicking the embryonic development and therefor contributing to similar structure of the engineered tissue with improve structural and functional properties.
The concept of "by demand" technology is highly innovative and have great potential.

Our solution provides for the first time a completely personalized treatment where both the material and cells are derived from the patient, therefore, the implant do not provoke an immune response. Additionally, in this approach, the cells are differentiated within their final ECM 3D construct which allows mimicking the embryonic development and therefor contributing to similar structure of the engineered tissue with improve structural and functional properties.
The concept of "by demand" technology is highly innovative and have great potential.

pre clinical studies in preparation to 1st human clinical trials